Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
Fiche publication
Date publication
août 2020
Journal
Expert opinion on biological therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD). After its patent expired other manufactures developed biosimilar versions, among which CT-P13, and licensed them thorough an expedite process.
Mots clés
CT-P13, Crohn’s disease, Inflectra®, Remicade®, Remsima®, biosimilar, inflammatory bowel disease, infliximab, intravenous, subcutaneous, ulcerative colitis
Référence
Expert Opin Biol Ther. 2020 Aug 17;: